"One little fly in the ointment here is that the QoL is only significant in the ITT group and not the PP."
The last question in the conference call touched on that issue. Management stated that they only presented what the investigator had presented at the conference. Management seemed to indicate that it was effectively based on what treatment was received, i.e. per protocol, though on pages 23-26 of presentation, it seems there were 26 patients who received sorafenib instead of SIRT, but were included in the SIRT saftey profile; consistent with ITT protocol.
But there is no PP presented for safety, so how did you assert "QoL is only significant in the ITT group and not the PP."
If anything, the PP data will be stronger given over 10% of the SIRT patient safety profile presented were hampered by being treated with sorafenib.
- Forums
- ASX - By Stock
- SRX
- Ann: SARAH Clinical Study Results Investor Presentation
Ann: SARAH Clinical Study Results Investor Presentation, page-26
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
(20min delay)
|
|||||
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.40M |
Open | High | Low | Value | Volume |
17.5¢ | 18.0¢ | 17.5¢ | $61.98K | 351.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 11238850 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 1266857 | 36 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 11238850 | 0.175 |
1 | 164705 | 0.170 |
1 | 18187 | 0.165 |
1 | 2577 | 0.097 |
1 | 4000 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 1246997 | 29 |
0.185 | 5000 | 1 |
0.190 | 315669 | 6 |
0.195 | 20478 | 2 |
0.200 | 181416 | 6 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |